Biontech SE, the German biotechnology company known for its COVID-19 vaccine, has reported a net loss of approximately €700 million for the fiscal year 2024. This marks a significant decline from the €9.4 billion profit reported in 2022, followed by a profit of about €930 million in 2023. The losses are attributed to substantial investments in clinical trials, particularly for its cancer treatment programs, which have resulted in decreasing earnings.

The company's revenues have also fallen sharply, from €3.8 billion in 2023 to approximately €2.75 billion in 2024. Projections for the current fiscal year suggest revenues will further decline to between €1.7 billion and €2.2 billion, while research and development expenditures are anticipated to remain high at €2.6 billion to €2.8 billion.

In response to these financial challenges, Biontech announced a reduction of its workforce, planning to cut between 950 and 1,350 full-time equivalent positions across Europe and North America by the end of 2027. The company emphasized that the layoffs would be managed in a socially responsible manner.

By the end of 2024, Biontech expects to have approximately 7,200 employees, of which about 70% were hired within the last three years.

Among the impacted sites is the Marburg facility, which is set to reduce its workforce from 670 to between 250 and 350 positions due to decreased demand for its mRNA production capabilities that had been expanded for vaccine manufacturing.

Additionally, the Idar-Oberstein location, currently housing 450 positions, is expected to see a reduction of up to 150 jobs.

Simultaneously, Biontech plans to expand its workforce in other areas, specifically at its Mainz headquarters, where it anticipates adding around 350 full-time positions in the current year.

The Mainz site remains central to Biontech’s operations, particularly in mRNA development, including both oncology products and vaccines for infectious diseases.

The company has been advancing its plans for mRNA-based cancer therapies with an aim to market the first products by 2026.

Biontech is focusing on developing immune-based therapies to help patients’ immune systems recognize and destroy cancer cells.

The company has made significant progress in developing treatments for bladder cancer and colorectal cancer, with pivotal new study data expected by the end of this year or early next year.

Biontech’s Chief Executive Officer Uğur Şahin noted that attention is particularly directed toward the year 2030, when multiple products are anticipated to reach the market, contingent on the outcomes of ongoing studies.

A key candidate in Biontech's pipeline is BNT327, which aims to counteract mechanisms employed by tumors to suppress the immune system, targeting conditions such as lung cancer and breast cancer.

Biontech acquired the global rights to BNT327 through its acquisition of the Chinese company Biotheus.

Currently, six late-stage Phase 3 studies are underway, five of which involve BNT327.

Successful study outcomes could lead to initial product approvals, enabling Biontech to explore combinations with existing therapies, including chemotherapy.

As Biontech navigates this challenging landscape, Şahin highlighted the critical need for timely advancement of clinical trials and emphasized the importance of a diverse portfolio of drug candidates, given the competitive nature of cancer treatment development.